CP 690,550,
CP 690550,
CP-690,550,
CP-690550,
CP690550,
tasocitinib,
tofacitinib,
tofacitinib citrate,
Xeljanz,
Tofacitinib,
Tasocitinib,
477600-75-2,
3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
CP-690550,
CP 690550,
racemic-tofacitinib,
1259404-17-5,
tofacitinibum,
Tofacitinib (CP-690550,Tasocitinib),
CP-690,550,
UNII-87LA6FU830,
3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile,
CHEMBL221959,
CHEBI:71200,
87LA6FU830,
MFCD11035919,
1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-, (3R,4R)-,
3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-[(3R,4R)-4-methyl-3-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile,
3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile,
Tofacitinib [USAN:INN],
C16H20N6O,
3eyg,
3fup,
3lxk,
4oti,
AK-68808,
MI1,
Tofacitinib (USAN),
PubChem16767,
tofacitinib-cp-690550,
CP-690550(Tasocitinib),
SCHEMBL322753,
GTPL5677,
QCR-53,
CTK3J8304,
HSDB 8311,
DTXSID90197271,
EX-A205,
UJLAWZDWDVHWOW-YPMHNXCESA-N,
BCPP000274,
AOB87470,
KS-000001IG,
KS-000006RA,
ZINC3818808,
ABP000824,
ANW-51607,
BDBM50193995,
CP-690,
s2789,
AKOS005145814,
AKOS005258733,
AC-8193,
BCP9000550,
CA10005,
CC-1770,
CS-0050,
DB08895,
GS-6106,
PB20522,
RL03781,
SB20004,
SB20005,
NCGC00229511-02,
NCGC00229511-04,
NCGC00244463-01,
Tofacitinib (CP-690550, Tasocitinib),
AJ-45724,
AK172116,
BC660087,
CP690550(Tasocitinib)/CP-690550,
HY-40354,
SC-21829,
TZ000640,
AB0007916,
TR-009964,
TX-016530,
FT-0083764,
W6440,
D09970,
Q-9324,
AB01565786_02,
600M752,
J-524314,
BRD-K31283835-001-01-9,
BRD-K31283835-048-04-4,
3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyr,
3-((3R,4R)-4-Methyl(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yi)Amino)Piperidin-1-Yl-3-Oxopropaneni,
(3R,4R)-3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile,
(3R,4R)-4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidine propanenitrile,
3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitr,
3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-1-piperidyl]-3-oxo-propanenitrile,
3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]piperidin-1-yl}-3-oxo-propionitrile,
3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile,
3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo(2,3-d)pyrimidin-4-yl-, (3R,4R)-,
dichloro[(r)-(+)-2,2-bis(diphenylphosphino)-1,1-binaphthyl][(1r,2r)-(+)-1,2-diphenylethylenediamine],
dichloro[(r)-(+)-2,2-bis(diphenylphosphino)-1,1-binaphthyl][(1r,2r)-(+)-1,2-diphenylethylenediamine]ruthenium(ii),
Xeljanz,
Tofacitinib citrate,
racemic-Tasocitinib,
Xeljanz (TN),
Tofacitinib [USAN],
D0EG1I,
D0O2KL,
cc-396,
MFCD11616529,
Tofacitinib, 99% - 10MG 10mg,
ACN-031566,
CID9926791,
CS-O-10853,
CID 9926791,
CP690550,
A4138,
CP 690,550,
C479163,
212143-23-2,
(3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile,
3-(4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
916591-01-0,
937669-80-2,